Incidence of Grades 3–4 Adverse Events Stratified by Continuous vs. Rechallenge Treatment
| Continuous treatment (n = 43) | Rechallenge treatment (n = 68) | After rechallenge (n = 68) | ||||
|---|---|---|---|---|---|---|
| Event | Grade 3 | Grade 4 | Grade 3 | Grade 4 | Grade 3 | Grade 4 |
| Hematologic | ||||||
| Leukocytopenia | 1 (2.3) | 0 (0.0) | 2* (3.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Neutropenia | 1† (2.6) | 0 (0.0) | 0‡ (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Anemia | 7 (16.3) | 0 (0.0) | 13 (19.1) | 0 (0.0) | 10 (14.7) | 0 (0.0) |
| Thrombocytopenia | 3 (7.0) | 0 (0.0) | 2 (2.9) | 1 (1.5) | 2 (2.9) | 1 (1.5) |
| Renal | ||||||
| Decrease in GFR | 2 (4.7) | 0 (0.0) | 5 (7.4) | 0 (0.0) | 5 (7.4) | 0 (0.0) |
| Adverse event leading to discontinuation | 5 (11.6) | 10 (14.7) | 10 (14.7) | |||
| Adverse event leading to dose reduction | 7 (16.2) | 10 (14.7) | 10 (14.7) | |||